After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Aldeyra Therapeutics for its New Drug Application of reproxalap for the treatment of dry eye dis ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced ...

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed ...

Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.

Aldeyra Therapeutics shares fell 70% after the FDA issued a third rejection for its dry-eye drug, citing a lack of evidence ...

Used the gel for dry eyelids. Twice a day for the first few days, now once a day. Completely cleared up with a couple of ...

Shares of Aldeyra Therapeutics fell sharply in premarket trading Tuesday said the U.S. health regulator rejected its dry-eye drug, saying that the company failed to show the treatment works. Shares ...

Nanodropper Inc. today announced the launch of the Eye Drop Score, a first-of-its-kind self-check quiz designed to help people who rely on prescription or over-the-counter eye drops better understand ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...